Multiple studies have shown that patients who have HER2-positive breast cancer, develop brain metastases, and receive trastuzumab have significantly improved overall survival than both HER2-positive patients who do not receive trastuzumab and HER2-negative patients, with a median overall survival from 12 to 24.9 months [45–48]. Here, ERBB2 is linked to breast carcinoma.